Targeted oral therapy reduces disease burden and improves symptoms for patients with rare blood disorder in trial

The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at The University of Texas MD Anderson Cancer Center.

Revolutionizing probiotic therapy: The emergence of CRISPR-Cas engineered strains

Probiotics, defined as live microorganisms beneficial to health, have shown promise in areas like anti-inflammatory activity and brain function, etc. However, challenges remain due to variability in tolerance and colonization among species and strains. Recent advances in genome engineering, including CRISPR-Cas, have facilitated the creation of novel probiotic strains, offering potential treatments for metabolic disorders, inflammation, infections, and cancer.

Persons with disabilities want Braille motion back in Parley

By Millennium Reporter

THE Kitwe Association for Persons with Disabilities has urged Parliament to revisit the decision to reject a motion advocating for the inclusion of braille writing and sign language as optional subjects in schools.

This content is locked

This is exclusive material. To read full story, click on register and choose one of the premium subscriptions to view this content. Login if you are already a premium user.